Markets:

Overview

News

Currencies

International

Treasuries

Dogwood Therapeutics, Inc. - Common Stock (NQ:DWTX)

2.590 -0.040 (-1.52%)

Streaming Delayed Price Updated: 10:28 AM EDT, Sep 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dogwood Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment ↗

September 01, 2026

Dogwood Therapeutics (NASDAQ:DWTX) said its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients and is expected to...

Via MarketBeat

Dogwood Therapeutics (NASDAQ:DWTX) Beats EPS Estimates in Q1 2026, Phase 2b Trial on Track ↗

May 14, 2026

Via Chartmill

DWTX Stock Heads For Worst Day In 9 Months As Chemotherapy Pain Drug Interim Study Data Fails To Boost Investor Confidence ↗

December 22, 2025

The company said that Halneuron demonstrated separation from placebo treated patients in terms of pain improvement but did not detail the scale of the said improvement.

Via Stocktwits

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

December 02, 2025

Via ACCESS Newswire

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

November 11, 2025

Via ACCESS Newswire

Dogwood Therapeutics Inc (NASDAQ:DWTX) Reports Q3 2025 Results, Focuses on Key Halneuron® Data ↗

November 06, 2025

Dogwood Therapeutics reports a Q3 2025 earnings miss but highlights key progress for its Halneuron® Phase 2b trial, with interim analysis on track for late 2025.

Via Chartmill

Topics Earnings

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

October 30, 2025

Via ACCESS Newswire

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

October 14, 2025

Via ACCESS Newswire

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

October 07, 2025

Via ACCESS Newswire

Which stocks are moving before the opening bell on Thursday? ↗

October 02, 2025

Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 02, 2025

Via Benzinga

Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket ↗

October 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 29, 2025

Gainers cbdMD (AMEX:YCBD) shares rose 116.3% to $1.35 during Monday's regular session. The company's market cap stands at $5.5 million. Zura Bio (NASDAQ: ZURA) stock moved upwards by 42.94% to $3.44....

Via Benzinga

Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug ↗

September 29, 2025

In return for the license, Sepin Pharma and its designated affiliates will get 7.31% of Dogwood’s common stock, on a fully diluted basis.

Via Stocktwits

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 29, 2025

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.

Via Benzinga

Here are the top movers in Monday's session. ↗

April 21, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Which stocks have an unusual volume on Monday? ↗

April 21, 2025

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

Via Chartmill

Top movers analysis in the middle of the day on 2025-04-21: top gainers and losers in today's session. ↗

April 21, 2025

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 21, 2025

Via Benzinga

The market is filled with gapping stocks in Monday's session. ↗

April 21, 2025

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

Nasdaq Tumbles Over 400 Points; Netflix Posts Upbeat Earnings ↗

April 21, 2025

Via Benzinga

Which stocks are moving on Thursday? ↗

April 17, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 17, 2025

Via Benzinga

Tuesday's after hours session: top gainers and losers ↗

April 15, 2025

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 15, 2025

Via Benzinga

Top stock movements in today's session. ↗

April 15, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Tuesday's session: top gainers and losers ↗

April 15, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 15, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 14, 2025

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.